Back to Trials
NCT07209371PHASE2Recruiting

Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance

Fred Hutchinson Cancer Center

Start Date

1/22/2026

Completion Date

5/1/2028

Summary

This phase II trial compares the effect of rifaximin to no intervention for the treatment of IgA monoclonal gammopathy of undetermined significance (MGUS). Rifaximin is a type of antibiotic that is only used in cancer chemotherapy (antineoplastic antibiotic). It works by damaging the cell's DNA and may kill cancer cells or precancerous cells like those found with MGUS. Giving rifaximin may kill more precancerous cells in patients with IgA MGUS.

Detailed Description

OUTLINE: Patients are randomized to 1 of 2 arms. ARM A: Patients receive rifaximin orally (PO) three times daily (TID) for 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study. ARM B: Patients undergo blood sample collection throughout the study. After completion of study intervention, patients are followed up at 90 days.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Age ≥ 18 years * Ability to understand and willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of potential study participants * Clinical diagnosis of IgA monoclonal gammopathy of undetermined significance (MGUS) based on International Myeloma Working Group (IMWG)-2014 criteria (Rajkumar et al, Lancet Oncology, 2014) * Agree to use adequate contraception * For women of child-bearing potential: prior to study entry and for the duration of study participation * For men: prior to study entry, for the duration of study participation, and one month after completion of rifaximin administration (for men) * No antibiotic use in the preceding 2 weeks Exclusion Criteria: * Participants who are receiving other investigational agents * Pregnant women * Known hypersensitivity to rifaximin

Interventions

DRUG

Rifaximin

PROCEDURE

Biospecimen Collection

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

IgA Monoclonal Gammopathy of Undetermined Significance

Locations

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington 98109

United States